This report explores insights from veteran biopharma and biotech executives on how they are focusing their efforts on process intensification.
Innovative treatments bring with them immense promise for patients who have few options. Delivering on this promise calls for developers to address inefficiencies across their workflows to be able to meet demand. Process intensification — taking steps to automate workflows, reduce bottlenecks and improve overall throughput — is quickly becoming important to sustainably bring innovative therapeutics to market.
This report explores insights from more than 150 veteran biopharma and biotech executives on how they are focusing their efforts to streamline manufacturing strategy to increase throughput. They report on their challenges and potential for significant gains. Highlights include:
- How biopharma and biotech companies were using process intensification in preclinical, clinical, and commercial manufacturing.
- The concerns among companies that are not yet pursuing process intensification.
- How AI-assistance is a key focus and is poised to accelerate intensification.
Offered Free by: BioPharma Dive’s Studio by Informa TechTarget and Thermo Fisher Scientific
See All Resources from: BioPharma Dive’s Studio by Informa TechTarget and Thermo Fisher Scientific
